Article
Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine.
Molecular cancer therapeutics - 1 Dec 2012
Wilmott James S, Tembe Varsha, Howle Julie R, Sharma Raghwa, Thompson John F, Rizos Helen, Lo Roger S, Kefford Richard F, Scolyer Richard A, Long Georgina V
Abstract excerpt
Targeted therapies are increasingly being used to treat a variety of cancers. Their efficacy depends upon the accurate detection and targeting of a specific mutation or aberration in the tumor. All cancers, such as melanoma, are molecularly heterogeneous, with drug-resistant subclones present before the treatment or emerging as a result of targeted therapies. Here, we show intralesional molecular heterogeneity in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.